 SAN JOSE, Calif., Sept. 30, 2019 PRNewswire -- Aridis Pharmaceuticals, Inc. ARDS, a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has consummated a licensing agreement with Serum AMR, an affiliate of Serum International BV SIBV and the Serum Institute of India, Ltd. The agreement grants Serum AMR a license to multiple programs from Aridis for certain limited territories and access the Companys MabIgX platform technology for asset identification and selection. As part of the agreement, Aridis will receive the remaining upfront cash payment of 10 million, which is in addition to the 5 million that was initially received when the companies signed an option agreement on July 30, 2019. 